TY - JOUR

T1 - Prediction of preeclampsia based on maternal serum endoglin level in women with pregestational diabetes mellitus

AU - Kapustin, Roman V.

AU - Kopteeva, Ekaterina V.

AU - Alekseenkova, Elena N.

AU - Korenevsky, Andrey V.

AU - Smirnov, Ilya V.

AU - Arzhanova, Olga N.

N1 - Publisher Copyright: © 2022 Informa UK Limited, trading as Taylor & Francis Group.

PY - 2022

Y1 - 2022

N2 - PURPOSE: To evaluate the level of soluble endoglin (sEng) in pregnant women with pregestational diabetes mellitus (DM) and to assess its predictive value for preeclampsia development.METHODS: Ninety pregnant women were enrolled in the study forming five comparison groups: type 1 DM (not planned, n = 20; planned, n = 20), type 2 DM (diet, n = 15; insulin therapy, n = 20), and the control group (n = 15). The primary outcome was clinically confirmed preeclampsia. Maternal serum concentrations of sEng were measured at 11+0-13+6 and 30+0-33+6 weeks.RESULTS: sEng level was elevated in all patients with pregestational DM compared to the control group. Its plasma concentration increased with gestational age and in case of preeclampsia development. In patients with type 1 DM, serum sEng level did not depend on the presence of preeclampsia. This is evidence of severe metabolic disorder and endothelial dysfunction in these patients. The addition of sEng level to logistic models considering established risk factors (body mass index + age + HbA1c level) in the first and third trimesters significantly improved their performance for preeclampsia prediction.CONCLUSIONS: Eng level may become an important marker for early prediction of preeclampsia in women with pregestational DM.

AB - PURPOSE: To evaluate the level of soluble endoglin (sEng) in pregnant women with pregestational diabetes mellitus (DM) and to assess its predictive value for preeclampsia development.METHODS: Ninety pregnant women were enrolled in the study forming five comparison groups: type 1 DM (not planned, n = 20; planned, n = 20), type 2 DM (diet, n = 15; insulin therapy, n = 20), and the control group (n = 15). The primary outcome was clinically confirmed preeclampsia. Maternal serum concentrations of sEng were measured at 11+0-13+6 and 30+0-33+6 weeks.RESULTS: sEng level was elevated in all patients with pregestational DM compared to the control group. Its plasma concentration increased with gestational age and in case of preeclampsia development. In patients with type 1 DM, serum sEng level did not depend on the presence of preeclampsia. This is evidence of severe metabolic disorder and endothelial dysfunction in these patients. The addition of sEng level to logistic models considering established risk factors (body mass index + age + HbA1c level) in the first and third trimesters significantly improved their performance for preeclampsia prediction.CONCLUSIONS: Eng level may become an important marker for early prediction of preeclampsia in women with pregestational DM.

KW - эндоглин

KW - беременность

KW - сахарный диабет

KW - преэклампсия

KW - diabetes mellitus

KW - Endoglin

KW - preeclampsia

KW - pregestational diabetes

KW - pregnancy

KW - Humans

KW - Pregnancy Trimester, Third

KW - Vascular Endothelial Growth Factor Receptor-1

KW - Pregnancy

KW - Pregnancy in Diabetics

KW - Pre-Eclampsia

KW - Diabetes Mellitus, Type 1

KW - Female

UR - http://www.scopus.com/inward/record.url?scp=85129827659&partnerID=8YFLogxK

UR - https://www.mendeley.com/catalogue/992bf3cd-6470-35a0-a108-4a5d3ca67ee7/

U2 - 10.1080/10641955.2022.2068574

DO - 10.1080/10641955.2022.2068574

M3 - Article

C2 - 35475412

AN - SCOPUS:85129827659

VL - 41

SP - 173

EP - 180

JO - Hypertension in Pregnancy

JF - Hypertension in Pregnancy

SN - 1064-1955

IS - 3-4

ER -